Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8787 results

  1. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    Awaiting development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. BioTime's Premvia HyStem hydrogel for the management of a wide range of wounds

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. MT660 CerebAir for monitoring continuous, real-time EEG

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. STS101 for treating acute migraine [TSID11782]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 20 April 2026.

    Technology appraisal guidance
    In consultation